✦ LIBER ✦

Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma

✍ Scribed by Heakal, Y.; Kester, M.; Savage, S.

Book ID: 111974376
Publisher: Harvey Whitney Books Company
Year: 2011
Tongue: English
Weight: 164 KB
Volume: 45
Category: Article
ISSN: 1060-0280
DOI: 10.1345/aph.1q363

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

330 INVITED The Development of Vemurafen

330 INVITED The Development of Vemurafenib for BRAF-mutated, Metastatic Melanoma

✍ F. Borellini 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 38 KB

1403 POSTER DISCUSSION Molecular Testing

1403 POSTER DISCUSSION Molecular Testing for BRAF V600 Mutations in Clinical Trials of the BRAF Inhibitor Vemurafenib (RG7204/PLX4032) in Metastatic Melanoma – a Comparison With Sánger Sequencing

✍ S. Anderson; K. Bloom; R. Schilling; J.R.J. Lee; R. Langland; H. Halait; H.J. La 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Incidence of the V600K mutation among me

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

✍ Jill C Rubinstein; Mario Sznol; Anna C Pavlick; Stephan Ariyan; Elaine Cheng; An 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 918 KB

Vemurafenib for the Treatment of Locally

Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal

✍ Beale, Sophie; Dickson, Rumona; Bagust, Adrian; Blundell, Michaela; Dundar, Yena 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 282 KB

Phase II Trial of Saracatinib (AZD0530),

Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer

✍ Ayca Gucalp; Joseph A. Sparano; James Caravelli; Jean Santamauro; Sujata Patil; 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 477 KB